BIO Asia-Taiwan 2024 opens July 24th

May 14, 2024 08:12 PM AEST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Global biotech opportunities viewed with an Asian touch

Conference Expands into Three Tracks: Innovation & Technology, Investment, and Regional Cooperation

Participation from 50 countries, with record number of exhibition booths

TAIPEI, May 14, 2024 /PRNewswire/ -- The 2024 BIO Asia–Taiwan conference, jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO), will be held July 24th to 28th at the Taipei Nangang Exhibition Center, TaiNEX 1 and 2. This year, the conference is expanding into three tracks: a three-day Innovation & Technology Forum; a two-day Investment Summit, and a three-day Regional Cooperation Forum. The exhibition is expected to host over 800 flagship companies utilizing 2,100 booths, and is expected to attract biomedical industry professionals from more than 50 countries.

Wu Chung-Hsiun, Chairman of Taiwan BIO, announced today that the theme of BIO Asia–Taiwan 2024 is "Global View, Asian Touch," This flagship event, along with the conference and exhibition, will feature the BIO One-on-one Partnering™ platform for business meetings, and a full schedule of company presentations. Recognizing Taiwan's biotech startup potential, the Taiwan Startup World Cup (TSWC), regional qualifiers for the Global Startup World Cup, will be held concurrently, and promises to attract the attention of both domestic and international investors.

Chairman of the BIO Asia–Taiwan 2024 Organizing Committee, Johnsee Lee, emphasized the focus on expanding investment and regional cooperation topics this year. "A three-day dedicated investment forum will be held, where a select group of 48 local and overseas companies will give 10-minute company presentations to the gathering of at least 50 prominent venture capital firms, including aMoon, the largest pharmaceutical venture capital fund in Israel; and Pegasus Tech Ventures, one of the top three venture capital companies in Silicon Valley. Our aim to elevate BIO Asia–Taiwan to the pinnacle of biotech investment events in Asia," he said.

And for the first time, BIO Asia–Taiwan will host a three-day Investment Summit Forum, with a strong lineup of invited VIP guests including John Tsai, Partner at Syncona Investment Management in the UK; Gur Roshwalb, Partner at aMoon; and Jack B. Nielsen, Partner at Wivace Capital Management, to discuss international biotech investment strategies.

Additionally, this year's Regional Cooperation Forum will for the first time be a collaboration between Taiwan BIO and the Taiwan External Trade Development Council. "We have invited Japan, Australia, Belgium, Malaysia, Thailand, India, the Philippines, and others, to host forums to discuss biotech investment, regulations, and business cooperation opportunities in their respective countries," Lee said.

The exhibition is expected to surpass last year's gathering in scale, with space for more than 800 exhibitors over 2,100 booths. Exhibition zones will cover CDMO (Contract Development and Manufacturing Organizations), Pharmaceuticals and Medical Devices, Cell and Regenerative Medicine, and Precision Medicine.

CDMO companies featured include Taiwanese firms EirGenix, Formosa Laboratories, Bora Pharmaceuticals, Taimed Biologics, Mycenax, TFBS Bioscience, Genovior Biotech, Level Biotechnology, Amaran Biotech, and UBI Pharma.

In the Pharmaceuticals and Medical Devices zone, local companies include PharmaEssentia, MycoMagic Biotechnology, Golden Biotechnology, Wendy International, Foresee Pharmaceuticals, Formosa Pharmaceuticals, AP Biosciences, Taho Pharmaceuticals, TSH Biopharm, TCM Biotech International, BoYen Therapeutics, and WCC Biomedical.

Precision Medicine companies include Quark Biosciences, Genomics, Starmoontech, and Cold Spring Biotech.            

The Cell and Regenerative Medicine zone will feature Mitek Lab, ACRO Biomedical ChainHome Biotech, Bertec Enterprise and Supercell Biotechnology.

The International Zone will feature pavilions from the US, Canada, Belgium, Switzerland, the Phillipines, India, Poland and others. And multinational companies hosting booths include Takeda, BMS, BD, IQVIA, Fujifim, Thermo Fisher, Wuxi Biologics, Ajinomoto, and Genscript.

This year's conference will include sessions that focus on industry trends and the latest technological developments. An impressive lineup of international speakers has been confirmed, including James and Patricia Poitras MIT professor and Tang Prize laureate, Prof. Zhang Feng, to share insights on biodiversity research; Zubin J. Daruwalla, Head of PwC Singapore's Health Business Division, named one of the 50 most influential figures in the global healthcare sector, to share latest industry trends; and Anis Uzzaman, Chairman of the Global Startup World Cup, to discuss the future prospects of the biotech industry from the perspective of international venture capital.

The organizing committee of BIO Asia–Taiwan is certain that this year's event will be the best yet! Be quick, exhibition space is filling up quickly, and Early Bird discounts are available for the conference tracks and business matching meetings only until June 19th. Whether participating in the exhibition, attending the conference or arranging business meetings, seize the opportunity and register now!

Contact:
Daisy Tsai
Taiwan Bio Industry Organization (Taiwan BIO)
Ph: 0933-139647
Line ID: daisy222
[email protected]
www.bioasiataiwan.com


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.